Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. - Wikidata - wikimedia - TriplyDB

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

http://www.wikidata.org/entity/Q37368085

about

Pharmacotherapies for obesity: past, current, and future therapies Narrative review: the role of leptin in human physiology: emerging clinical applications The Use of Rat and Mouse Models in Bariatric Surgery Experiments The Rationale for Insulin Therapy in Alzheimer's Disease New advances in the treatment of generalized lipodystrophy: role of metreleptin Obesity pharmacotherapy: current perspectives and future directions Adipose tissue and adipokines: the association with and application of adipokines in obesity Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism The brain and brown fat Adipokines - removing road blocks to obesity and diabetes therapy Neural control of energy balance: translating circuits to therapies Next generation of weight management medications: implications for diabetes and CVD risk Obesity: Current and potential pharmacotherapeutics and targets.Antiobesity pharmacotherapy: new drugs and emerging targets New advances in models and strategies for developing anti-obesity drugs.Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity.Leptin revisited: its mechanism of action and potential for treating diabetes.Combinations of drugs in the Treatment of Obesity.Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium.Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.Obesity pharmacotherapy: what is next?Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.Cellular bioenergetics as a target for obesity therapy.Pramlintide and the treatment of diabetes: a review of the data since its introduction.Amylin activates distributed CNS nuclei to control energy balance.Comparative endocrinology of leptin: assessing function in a phylogenetic context Leptin in human physiology and therapeutics Agile delivery of protein therapeutics to CNS Obesity and leptin resistance: distinguishing cause from effect.Pharmacological management of binge eating disorder: current and emerging treatment options.New pharmacological perspectives for the leptin receptor in the treatment of obesity Metreleptin: first global approval.Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans.Pharmacological treatment of obesity in children and adolescents: present and future Novel strategy for the use of leptin for obesity therapy In vivo metabolic imaging of insulin with multiphoton fluorescence of human insulin-Au nanodots.Behavioral and pharmacologic therapies for obesity.The great debate: medicine or surgery: what is best for the patient with type 2 diabetes?Chronic elevation of systemic glucagon-like peptide-1 following surgical weight loss: association with nausea and vomiting and effects on adipokines

P2860

Q21296814-B55D8D9B-B528-44E5-B8B4-B763B8027876 Q24634811-739B464E-C87F-41B1-B120-6CA9407A235E Q26740015-8AAFE424-4A99-4E76-8259-04F1E1C399D2 Q26744834-96E50FD7-1324-4E7D-A2F9-FF84ABD00085 Q26781946-92050CA0-F196-4C63-AA46-F855C00D9240 Q26828559-4E4F3F9A-41BA-4A85-8207-C28D96A97240 Q26830052-922B1312-46C9-4EA2-B11F-AD6CF00AEE7E Q26859118-142767ED-810B-4BCC-984B-772D043ECF0F Q26864148-A9A17C5C-365F-4790-AEDC-E1059F80BE00 Q26865368-0E0ED1D7-E907-4143-8E48-4132FD1E6D28 Q26995825-0B19C2B2-9BA3-4A80-8584-8D254C08B0DD Q27005992-81D65E63-6C4F-48B9-9A1E-BF8801594B83 Q28082858-3F9394E1-51FF-4CE3-A51F-B0E23E89267D Q30243992-6D368103-BD46-4900-8E6C-E8BDEE42980E Q30354242-1A6709E4-69BD-454E-ABEE-580EFE8D5C07 Q30429816-352B4A52-6CBE-4856-A222-E6A1CD59C211 Q30592302-67F69078-D73A-4062-A945-A29F1A6DD962 Q33602487-786BF24B-2D26-4804-8957-93D12B37051E Q33664063-4CE29491-FB0E-43B6-AD94-057761D407D6 Q33723458-1827203E-7C1B-482E-956A-FC6FDAC1D2FB Q33789329-ACC0DB2D-F6F0-48A0-A1B5-9E2DD39950B4 Q33827988-5A476689-E7CD-4B33-BAFA-F69BEBAF221E Q33838133-5DE659C8-BA92-470F-8341-8F8B74689554 Q33894407-EF80325E-47E8-4854-8449-59ED0EFB5B4C Q33896433-3DD7DE68-1248-48A7-B56C-9BA28407CA8E Q33962500-E1BFDA19-11E6-4FAB-9F77-C8324FAF9C96 Q34028808-A578C23E-728C-4D54-97A0-50A6194A86E2 Q34047024-6184B340-955A-4411-9387-43AD32BAF8B4 Q34079647-4515EED9-9949-48D1-B973-08BBAC783215 Q34259053-88FB8565-BCF4-4C61-9522-3A18F5E99886 Q34278450-D66EF07F-6412-4B32-9900-52B1DAD6EE17 Q34330557-A6A2F5F3-7C7A-4FF9-B32F-C48F9703397E Q34348966-B3719A1E-30DC-47A7-93A8-E3569BAB9EAE Q34422087-11B933F4-684F-4147-B378-99E4489F5239 Q34442880-C74C9F42-B854-4448-BC59-69F3CB62F1A6 Q34454718-C3C7B126-7DB6-45AF-B5A3-DA11A1EAF3D2 Q34484985-E9C8E507-F521-4E83-B8A9-26F3C7E1F00F Q34543656-FD951030-ED5D-4934-87E3-316BF5823914 Q34583457-63E0E4FF-F06C-403C-BC5E-38EA99EBF59D Q34978556-7FF67BA2-6052-40F7-B3AE-E1EB78B6DC39

P2860

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

http://www.wikidata.org/entity/Q37368085

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@en

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@nl

type

label

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@en

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@nl

prefLabel

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@en

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@nl

P1433

Q37368085-6BB0572E-8657-41C4-A853-B07944071A96

P1476

Q37368085-2CDA88FA-4C4A-48BC-B65D-1453D755B469

P2093

Q37368085-09DA3128-3E28-417B-9AAA-FB946DE75C65

Q37368085-427AF938-1A6F-4D65-878E-3984E48DB279

Q37368085-65A92097-42EF-4784-A2DC-DDCEDDD553A2

Q37368085-A0E6DE5A-879E-4E62-9D66-B56B71813DD3

Q37368085-ACFDDD3A-ECD6-436C-8B6C-F609D4182B35

Q37368085-BE8818B9-7EA7-40E8-B95F-1EFA2188C90A

Q37368085-C72B2C58-3C7B-4638-B117-79EA85C41CE4

P2860

Q37368085-0003B599-AD36-4D6F-BAAD-1993B3F85EB8

Q37368085-04808699-1102-489A-B891-CD39FB81F8FA

Q37368085-0858CF2A-7D35-4ECD-8BC5-553FBC15AAC9

Q37368085-0BCC454D-D0B4-40B7-8390-D676589CE44A

Q37368085-2166B14B-3F6B-447B-A4C1-4F03561B8ACA

Q37368085-24C24D3B-4E2A-4C9A-9807-745338F868E4

Q37368085-2619AA5B-775C-488D-81D2-CA6A7328306A

Q37368085-2EE01D7D-9073-4DCB-9FA4-4BC41CE253B7

Q37368085-4E635639-716A-4248-AC77-E59E95BA110B

Q37368085-67C3A907-406B-4436-8A84-5A77EAF1659B

P304

Q37368085-11B3D9EC-15E6-40B8-AB9A-58E352DE5DB3

P31

Q37368085-C42A3C20-FBCD-43C3-8872-C01D8005BBE9

P356

Q37368085-9E038AF2-E9E4-42E4-B6F7-266B8C0CC166

P433

Q37368085-EDE804A9-1F7A-4D80-92A8-C65F290A7CAB

P478

Q37368085-2DD62AC9-38E0-465A-B278-5F3139EA24EF

P50

Q37368085-86EC4CB8-2B0A-4587-97AE-A0F6F63E5761

P577

Q37368085-CE277E92-E493-4EF2-B613-24D9BC0C2464

P5875

Q37368085-0276FFED-687F-4408-A06E-0C496C069B31

P698

Q37368085-1C4E7947-A475-43BF-B78A-FE415CE04859

P921

Q37368085-08AA0423-EF27-40DF-8500-93DD9ADCD8AB

Q37368085-B7E9209C-7E2C-492A-9B7C-6ABA6998D972

P932

Q37368085-952DD663-C766-426E-BF00-0CE102D37D73

P356

P1433

P1476

Enhanced weight loss with pram ...... ch to obesity pharmacotherapy.

@en

P2093

Christian Weyer

http://www.w3.org/2001/XMLSchema#string

Holly Maier

http://www.w3.org/2001/XMLSchema#string

Joy E Koda

http://www.w3.org/2001/XMLSchema#string

Julie A Mitchell

http://www.w3.org/2001/XMLSchema#string

Kevin Shan

http://www.w3.org/2001/XMLSchema#string

Reshma Shringarpure

http://www.w3.org/2001/XMLSchema#string

Steven R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

The hospital anxiety and depression scale

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Congenital leptin deficiency is associated with severe early-onset obesity in humans

Leptin action in the forebrain regulates the hindbrain response to satiety signals.

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight.

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

Gastrointestinal regulation of food intake.

Pancreatic amylin as a centrally acting satiating hormone.

P304

1736-1743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/OBY.2009.184

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26287344

http://www.w3.org/2001/XMLSchema#string

P698

19521351

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

2754219

http://www.w3.org/2001/XMLSchema#string